Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06275373 · ClinicalTrials.gov registry record
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
A clinical trial of Thyroid Eye Disease and Graves Disease, sponsored by Walter Reed National Military Medical Center.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT06275373 is a study of Thyroid Eye Disease and Graves Disease that is actively recruiting participants, run by Walter Reed National Military Medical Center. The registered enrollment target is 100 participants, roughly in line with the 100-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT06275373, a study of Thyroid Eye Disease and Graves Disease, is actively recruiting participants, sponsored by Walter Reed National Military Medical Center.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment will be evaluated by an oculoplastic surgeon (Dr. Eva Chou) and endocrinologist (Dr. Thanh Hoang).
Conditions Studied
Interventions
- DRUG Teprotumumab Injection [Tepezza]
Study Locations (1)
Maryland
- Walter Reed National Military Medical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-05-12 |
| Est. Completion | 2027-12-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06275373
The ClinicalTrials.gov registry entry for NCT06275373 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 100-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target. The listed sponsor is Walter Reed National Military Medical Center, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Thyroid Eye Disease appearing as the primary indexed condition, and to 1 intervention - of which Teprotumumab Injection [Tepezza] is the first listed.
NCT06275373 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT06275373 about?
NCT06275373 is a clinical study titled "The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction". This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment...
What is the current status of trial NCT06275373?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2021-05-12. Estimated completion is 2027-12-12.
What conditions does trial NCT06275373 study?
This clinical trial studies the following conditions: Thyroid Eye Disease, Graves Disease, Graves Ophthalmopathy.
What interventions are being tested in trial NCT06275373?
The interventions under investigation include: Teprotumumab Injection [Tepezza] (DRUG).
Who is sponsoring clinical trial NCT06275373?
This trial is sponsored by Walter Reed National Military Medical Center, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06275373 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)
RECRUITING · Phase 1
-
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
RECRUITING · Phase 2
-
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
RECRUITING · Phase 1
-
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
RECRUITING · Phase 2
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.